2026-10-14T13:58:29Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33994659 2026-09-25T11:05:09Z category_7 portal_147 item_type_3 month_year_09_2026

Supplemental Material for: Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers figshare admin karger (2628495) Thitirat Supasil (25109458) Paramat Thimachai (25109461) Ouppatham Supasyndh (726105) Bancha Satirapoj (726102) Medicine Medicine <p dir="ltr"><b>Introduction:</b>Hydroxychloroquine (HCQ) has immunomodulatory and anti-inflammatory properties that may provide additional benefit in chronic proteinuric glomerulopathy (CGN). This study aimed to evaluate the short-term effects of adjunctive HCQ on proteinuria and inflammatory biomarkers in patients with stable CGN receiving optimized supportive therapy.</p><p dir="ltr"><b>Methods:</b>In this single-center, double-blind, placebo-controlled proof-of-concept randomized trial, 43 patients with CGN (urine protein-to-creatinine ratio ≥ 0.5 g/g and eGFR > 20 mL/min/1.73 m²) were randomized to receive eGFR-adjusted HCQ (n=21) or placebo (n=22) for 4 months. The primary outcome was change in proteinuria; secondary outcomes included interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), eGFR, and safety.</p><p dir="ltr"><b>Results:</b>After 4 months, the median percentage change in proteinuria was −27.9% (IQR, −55.1 to −15.5) with HCQ versus +20.7% (IQR, −6.9 to +45.4) with placebo. In mixed-effects maximum-likelihood regression adjusted for systolic blood pressure, HCQ was associated with a greater reduction in proteinuria than placebo (β, −118.55; 95% CI, −208.07 to −29.03; p = 0.009). A ≥ 30% reduction in proteinuria occurred more frequently with HCQ than placebo (50.0% vs. 14.3%; p = 0.014). IL-6 and hsCRP were also reduced with HCQ. No significant between-group difference in eGFR or serious adverse events was observed.</p><p dir="ltr"><b>Conclusion:</b>Adjunctive HCQ was associated with a short-term reduction in proteinuria in patients with stable chronic proteinuric glomerulopathy receiving optimized supportive therapy. Exploratory reductions in IL-6 and hsCRP were also observed. These proof-of-concept findings support further evaluation of HCQ in larger, longer, biopsy-based, disease-specific randomized trials.</p> 2026-09-25T11:05:09Z Dataset Dataset 10.6084/m9.figshare.33994659.v1 https://figshare.com/articles/dataset/Supplemental_Material_for_Effect_of_Hydroxychloroquine_on_Proteinuria_and_Inflammatory_Markers/33994659 CC BY 4.0